Xenon Pharmaceuticals Inc.’s filing revealed that its Director Svoronos Dawn unloaded Company’s shares for reported $0.97 million on Aug 24. In the deal valued at $38.70 per share,25,000 shares were sold. As a result of this transaction, Svoronos Dawn now holds 25,000 shares worth roughly $ 0.99 million.
Then, PIMSTONE SIMON N. sold 31,713 shares, generating $1,231,247 in total proceeds. Upon selling the shares at $38.82, the Director now owns 6,000 shares.
Before that, PIMSTONE SIMON N. sold 62,526 shares. Xenon Pharmaceuticals Inc. shares valued at $2,420,051 were divested by the Director at a price of $38.70 per share. As a result of the transaction, PIMSTONE SIMON N. now holds 6,000 shares, worth roughly $0.24 million.
Cantor Fitzgerald initiated its Xenon Pharmaceuticals Inc. [XENE] rating to an Overweight in a research note published on Friday, April 25, 2023; the price target was $58. PT values the company’s stock at a premium of 31.5 to its Friday closing price.
Price Performance Review of XENE
On Friday, Xenon Pharmaceuticals Inc. [NASDAQ:XENE] saw its stock jump 1.92% to $39.73. On the same session, the stock had its day’s lowest price of $39.09, but rose to a high of $40.135. Over the last five days, the stock has gained 4.42%. Xenon Pharmaceuticals Inc. shares have risen nearly 0.76% since the year began. Nevertheless, the stocks have risen 2.37% over the past one year. While a 52-week high of $43.75 was reached on 06/13/23, a 52-week low of $31.79 was recorded on 03/16/23. SMA at 50 days reached $37.95, while 200 days put it at $38.00. A total of 0.21 million shares were traded, compared to the trading of 0.39 million shares in the previous session.
Levels Of Support And Resistance For XENE Stock
The 24-hour chart illustrates a support level at 39.17, which if violated will result in even more drops to 38.61. On the upside, there is a resistance level at 40.21. A further resistance level may holdings at 40.70. The Relative Strength Index (RSI) on the 14-day chart is 61.27, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.24, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 7.80%. Stochastics %K at 92.03% indicates the stock is a selling.
How much short interest is there in Xenon Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Xenon Pharmaceuticals Inc. stocks on Aug 14, 2023, dropping by 50000.0 shares to a total of 2.72 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 2.77 million shares. There was a decline of -1.84%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 4.26% of the overall stock float, the days-to-cover ratio (short ratio) fell to 7.79.
Xenon Pharmaceuticals Inc. [XENE] – Who Are The Largest Shareholders?
In filings from Fidelity Management & Research Co, it is revealed that the company now owns 5,188,092 shares, or roughly 8.16% of the outstanding XENE shares. In other words, the investor’s shares have risen by 460,858 from its previous 13-F filing of 4727234.0.. At present, Marshall Wace LLP is holding 2,320,419 shares valued at $85.67 million. Capital Research & Management Co owned 2,274,974 shares of the company at the time of its most recent 13F filing, worth $83.99 million.
According to FactSet, Xenon Pharmaceuticals Inc.’s share price will average $52.69 in the next year, based on opinions of analysts polled by the firm. This is up nearly 33.4 percent from its previous closing price of $38.98. Analysts expect Xenon Pharmaceuticals Inc. stock to reach the higher price of $60.00, while the lowest price estimate is $46.00. However, 14 analysts have rated XENE stock as a Buy in their predictions for 2023.